Physician profile
Sandhya Vallem
NPI 1285002238
$734.71
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $81.60 · 2021: $205 · 2022: $317 · 2023: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $226.64 | 2020-2022 | |
| Abbvie INC. | $194.02 | 2022-2023 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.13 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $40.29 | 2020-2022 | |
| Novo Nordisk INC | $27.57 | 2020-2021 | |
| Mylan Specialty L.P. | $26.49 | 2021 | |
| Cranial Technologies, INC | $15.35 | 2021 | |
| Genentech USA, INC. | $15.02 | 2020 | |
| Pfizer INC. | $14.97 | 2023 | |
| Sanofi Pasteur INC. | $14.77 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.65 | 2022 | |
| Amgen INC. | $14.58 | 2022 | |
| Lilly USA, LLC | $13.67 | 2021 | |
| Merck Sharp & Dohme LLC | $11.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.61 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $8.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Vallem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.